Skip to main content

HPA Global

HPA-Global Member Niagen Bioscience Reports $27.2 Million in Third-Quarter Sales and Expands Healthy-Aging Business

November 4, 2026

HPA-Global member Niagen Bioscience has reported third-quarter 2026 net sales of $27.2 million, including $23.3 million generated by its flagship Tru Niagen brand.

The company reported a gross profit margin of 62.9%, positive adjusted EBITDA of $500,000 and a net loss of $1.2 million. Operating cash flow reached $2.6 million during the quarter, while cash and cash equivalents totaled $69.5 million at September 30.

Direct-to-consumer sales through the company’s website increased 13% year over year.

Beyond its financial performance, Niagen highlighted several developments across its expanding healthy-aging platform.

The company introduced a ready-to-inject liquid formulation of pharmaceutical-grade nicotinamide riboside through its Niagen Plus telehealth program and established Tru Niagen Skincare as a permanent business category following the introduction of NanoCloud.

Niagen also expanded its retail distribution through Walmart.com and approximately 300 GNC and Sam’s Club locations combined.

On the research side, the company announced a preliminary agreement with Mass General Brigham to begin planning what it expects to become its largest clinical trial involving Niagen.

However, management acknowledged competitive pressures affecting its ingredient business and expects ingredient sales for 2026 to finish below the previous year’s level.

To address these challenges, Niagen is developing a lower-cost patented nicotinamide riboside salt intended to improve manufacturing economics and strengthen its ingredient business.

What this means for the industry

Niagen’s financial results illustrate the growing diversification of companies specializing in healthy-aging ingredients.

Rather than relying exclusively on conventional dietary supplements, the company is expanding into pharmaceutical development, clinician-directed products, topical skincare and additional retail channels.

The planned lower-cost NR ingredient is particularly relevant to supplement manufacturers seeking more economical NAD+ precursor formulations.

At the same time, the company’s acknowledgment of ingredient-market competition demonstrates that scientific differentiation and intellectual property do not eliminate commercial pricing pressures.

Source: Niagen Bioscience, November 4, 2026.

Original source: Niagen Bioscience — Third Quarter 2026 Financial Results. Niagen Bioscience

About HPA-Global: HPA-Global supports dietary supplement, functional food and ingredient companies through international market intelligence, regulatory guidance, industry visibility and business connections across China, Greater Asia and other major markets.

For more details, visit www.hpaglobal.org/connect.